What were the revenue, net loss, and cash burn figures for the quarter, and how do they compare to the same quarter last year? | ACLX (Aug 07, 2025) | Candlesense
ACLX

What were the revenue, net loss, and cash burn figures for the quarter, and how do they compare to the same quarter last year?

Answer – Revenue, Net Loss, and Cash‑Burn for Q2 2025 (and comparison to Q2 2024)

Based on the excerpt you supplied from the Business Wire release titled “Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights,” the specific monetary figures for:

Metric Q2 2025 (ended June 30 2025) Q2 2024 (same quarter last year) Year‑over‑Year Change
Revenue not disclosed in the provided text not disclosed in the provided text –
Net loss not disclosed in the provided text not disclosed in the provided text –
Cash burn (cash used in operations) not disclosed in the provided text not disclosed in the provided text –

Explanation

  • The excerpt you shared contains the opening paragraph of the press release (company description, study update, and a partial sentence that cuts off after “
potential to be a life‑changing therapy for mu”).
  • None of the typical financial‑results tables or narrative paragraphs that normally follow the opening paragraph—where revenue, net loss, and cash‑burn numbers are presented—are included in the snippet.
  • Because the necessary quantitative details are absent, we cannot extract or infer the exact figures or the year‑over‑year differences.

What to do next

  1. Locate the full press release – The complete Business Wire announcement will contain a “Financial Highlights” section (often a table) that lists:

    • Total revenue (or “Revenue”) for the quarter
    • Net loss (or “Net loss attributable to shareholders”) for the quarter
    • Cash used in operating activities (commonly described as “cash burn”) for the quarter

  2. Check the company’s investor‑relations website – Arcellx (NASDAQ: ACLX) posts quarterly earnings releases and accompanying slide decks (often titled “Q2 2025 Financial Results”) that provide the exact numbers and a commentary on how they compare with Q2 2024.

  3. If you need a quick snapshot – You can also consult third‑party financial data platforms (e.g., Bloomberg, Yahoo Finance, Refinitiv) that aggregate quarterly earnings data for listed companies and will show the year‑over‑year changes.

Bottom line: The provided news excerpt does not contain the revenue, net‑loss, or cash‑burn figures for Q2 2025, nor the comparative numbers for Q2 2024. Access to the full earnings release is required to answer the question accurately.

Other Questions About This News

What is the current short‑interest and institutional ownership trend post‑release? What is the projected timeline for commercialization if the trial succeeds, and how does that affect peak revenue projections? Are there any upcoming catalysts (e.g., data readouts, conference presentations) that could drive short‑term volatility? When is the regulatory filing timeline for the 'iMMagine-1' study data and potential FDA submission? What are the implications of the 117‑patient data on the potential market size and pricing model for anito‑cel? How did Arcellx's Q2 2025 earnings compare to analyst expectations and consensus forecasts? What is the outlook for cash runway and upcoming financing needs? How does the enrollment and data from the 117‑patient registrational study impact the valuation of anito‑cel? How does the current valuation (P/E, EV/EBITDA) compare to other cell‑therapy companies such as CRISPR Therapeutics, CAR-T makers, etc.? Are there any changes in the management team or board that could affect strategy execution? How does the sentiment score of 40 translate into market sentiment or analyst revisions? What are the key risks highlighted in the 10‑Q filing and how might they affect the risk‑adjusted return? How does the current share price compare to historical averages and the company's current market cap? What are the prospects and timelines for any upcoming partnership or licensing deals?